Jazz Pharmaceuticals.
Irish tax-registered pharmaceutical corporation
- Reports this week
- 2
- Active events
- 2
- Connections
- 110
What's happening
Active this week
Earlier this month
One to three months ago
-
Alan M. Sebulsky was appointed to the Board of Directors of MeiraGTx Holdings PLC, where he has previously served.Some support1 report
-
Iambic Therapeutics announced multiple new partnerships, including collaborations with Jazz Pharmaceuticals and AbbVie, and received backing from Qatar Investment Authority and Nvidia.Well supported4 reports
-
The California State Teachers Retirement System has increased its stake in Jazz Pharmaceuticals.Some support1 report
-
Jazz Pharmaceuticals and RYTHM are competing in the pharmaceutical market and listed on the Nasdaq stock exchange.Some support4 reports
-
Jazz Pharmaceuticals acquires Actio Biosciences for rare epilepsy portfolio, and the company's investigational drug secures multiple FDA designations.Some support2 reports1 development inside
-
Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.Some support1 report
-
Jazz Pharmaceuticals guaranteed notes issued by its subsidiary, Jazz Investments I Limited, on August 26, 2026.Some support1 report
-
Jazz Pharmaceuticals received conditional marketing authorization in Europe and specific product approvals for Ziihera in Norway, Iceland, and Liechtenstein on July 6, 2025.Speculative3 reports2 developments inside
-
Vertex Pharmaceuticals and Jazz Pharmaceuticals initiated a collaboration on T-cell engager research programs.Some support1 report
-
Analyst coverage and company performance data published regarding Jazz Pharmaceuticals, involving MarketBeat, Royal Bank of Canada, and TD Cowen.Some support2 reports
-
Dr. Mark D. Smith holds a Clinical Professorship at UC San Francisco, serves on Jazz Pharmaceuticals boards, and was elected to the National Academy of Medicine in 2001.Some support1 report
Gone quiet
No new reports in 90+ days-
Morgan Stanley and Wells Fargo maintained 'Buy' ratings for Jazz Pharmaceuticals, citing benefits from tariffs and onshoring trends for AI stocks.Some support5 reports
-
Partnership between Jazz Pharmaceuticals, AbCellera, and PharmaMar leverages an antibody discovery engine for a biopharmaceutical based in Ireland.Well supported4 reports
-
Jazz Pharmaceuticals disclosed stock transactions via required filings with the SEC.Some support5 reports
-
FDA granted approval to Zepzelca in 2025, which was approved in partnership with Roche's Tecentriq.Some support1 report
-
A prostate cancer awareness campaign featuring Jazz Pharmaceuticals, George Kittle, and Delanie Walker took place in Cannes.Some support1 report
-
Morgan Stanley and Truist Financial have issued rating updates and price targets for Jazz Pharmaceuticals, requiring filings with the SEC.Some support1 report
-
Jazz Pharmaceuticals filed required documentation with the SEC regarding market transparency on June 11, 2026.Some support1 report
-
Analyst raised price target for Jazz Pharmaceuticals from $281 to $307, driven by product adoption and revenue growth.Some support1 report
-
Jazz Pharmaceuticals, headquartered in Dublin, Ireland, participated in the Wells Fargo Healthcare Conference.Some support5 reports
-
Jazz Pharmaceuticals received conditional marketing approval from the European Commission on July 1, 2025.Speculative1 report
-
Analyst questions were raised on August 13, 2025, regarding the sustainability of Xywav patient adds for Jazz Pharmaceuticals.Some support1 report
-
Microsoft, Elanco, Monster Beverage, and Jazz Pharmaceuticals were cited in thematic investing as examples of diverse winners in the pharmaceuticals segment.Some support2 reports
-
AbCellera and Jazz Pharmaceuticals are both companies operating within the biomedical industry.Some support1 report
-
Jazz Pharmaceuticals announced that Renee Gala was selected as the new CEO of the company on July 10, 2025. Bruce Cozadd previously held the CEO role.Some support1 report
-
Jazz Pharmaceuticals sued over LUMRYZ approval, which the FDA granted for narcolepsy treatment, leading to court rulings in the D.C. circuit.Some support2 reports
-
Jazz Pharmaceuticals and Jeld-Wen faced market challenges and tax inversion merger issues amid an aggressive tariff plan.Some support1 report
-
UBS reiterated a Buy rating on Jazz Pharmaceuticals on July 2, 2025.Speculative1 report
-
Jazz Pharmaceuticals relocated its headquarters to Ireland while an aggressive tariff plan caused markets to tank.Some support5 reports
-
Jazz Pharmaceuticals is facing inquiries from Bank of America regarding tariff risks and company matters.Speculative1 report
-
Seamus Mulligan bought shares of Jazz Pharmaceuticals on July 2, 2025.Speculative1 report
-
Thierry orchestrated the acquisition of Amolyt Pharma by AstraZeneca and the acquisition of his venture Alizé Pharma 2 by Jazz Pharmaceuticals.Speculative1 report
-
Jazz Pharmaceuticals stock declined 11% on July 8, 2025, while the S&P 500 saw a gain of 5.3%.Speculative1 report
-
Jazz Pharmaceuticals acquired GW Pharmaceuticals on July 14, 2025, and is now marketing FDA-approved cannabis drugs.Some support1 report
-
Benjamin Graham's investment philosophy is noted as guiding stock analysis for Jazz Pharmaceuticals.Some support1 report
-
Jazz Pharmaceuticals reported that oncology headwinds offset neuroscience momentum in its portfolio.Some support2 reports
-
Jazz seeks Priority Review from FDA and announces results from Dublin.Some support1 report
-
Jazz Pharmaceuticals acquired Chimerix in April 2025, and the FDA granted accelerated approval to Jazz Pharma's therapy on the same date.Some support1 report
-
Jazz Pharmaceuticals has a recently licensed medication called Modeyso, which was licensed as of September 2, 2025.Well supported5 reports
-
Jazz Pharmaceuticals licensed SAN2355 to Saniona for development on August 29, 2025.Well supported4 reports
No events began in the chosen period. Widen it, or reset.
What's reaching Jazz Pharmaceuticals
Events traced to Jazz Pharmaceuticals, step by step, newest firstAround Jazz Pharmaceuticals this week
News at the entities that move Jazz Pharmaceuticals most-
FDA StructuralFDA conducted surprise raids and inspections in Bihar state, directed by state government officials.Moves Jazz Pharmaceuticals
-
SEC StructuralCNBC reports on FED rate decisions and their impact on the Main Street economy and SEC yields.Moves Jazz Pharmaceuticals
-
Morgan Stanley OperationalBank of America and Morgan Stanley are restricting third-party AI agents amid cybersecurity scares and a declared bank run threat.Moves Jazz Pharmaceuticals
-
Food and Drug Administration StructuralSummit seeks FDA approval for its drug, which was presented at the ASCO meeting. The company is developing ivonescimab with Akeso.Moves Jazz Pharmaceuticals
-
Zymeworks StructuralZymeworks and Hoffmann-La Roche announced a collaboration agreement for the development of ZW209.Moves Jazz Pharmaceuticals
-
Ireland StructuralA documentary about Ireland's population was fronted, and individuals gave interviews to the Irish Independent.Moves Jazz Pharmaceuticals
Connections
The 35 strongest of 110, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Zymeworks Structural
A and B maintain a strategic partnership where B commercializes its assets using A's global reach, with financial milestones tied to A's regulatory successes.
-
FDA Structural
Jazz Pharmaceuticals relies on the FDA for regulatory approval, which is required for market introduction and sales of its therapies.
-
Chimerix (United States) Structural
Jazz Pharmaceuticals acquired Chimerix, establishing it as a subsidiary and gaining control over its assets.
-
SEC Structural
Jazz Pharmaceuticals must file required disclosures and transactions with the SEC to maintain market transparency.
-
Nasdaq Structural
Jazz Pharmaceuticals is listed on the Nasdaq stock exchange.
-
Ireland Structural
Jazz Pharmaceuticals is headquartered in Ireland, a status established following a tax inversion merger in 2012.
-
AbCellera Operational
The companies maintain an active partnership focused on joint collaboration and development of multispecific antibodies.
-
Morgan Stanley Operational
Morgan Stanley provides investment ratings and price targets for Jazz Pharmaceuticals, influencing market perception.
Show all 35 connections
-
Samsung Electronics Operational
Jazz Pharmaceuticals and Samsung Electronics have formed a strategic partnership to boost AI smartphone accessibility.
-
Johnson & Johnson Operational
The two companies are major pharmaceutical players who operate in the same competitive market space.
-
Securities and Exchange Commission Structural
Jazz Pharmaceuticals is subject to the filing and disclosure requirements of the U.S. Securities and Exchange Commission, including the 13F rule.
-
Elanco Operational
The two companies actively compete and operate within the specialized pharmaceutical market segment.
-
Mark D. Smith Structural
Mark D. Smith serves as a board member for Jazz Pharmaceuticals.
-
Food and Drug Administration Structural
Jazz Pharmaceuticals' market function is structurally dependent on regulatory approvals granted by the Food and Drug Administration.
-
Needham & Company Mentioned together
Needham & Company provides financial analysis and price target recommendations for Jazz Pharmaceuticals stock.
-
Bank of America Mentioned together
BoA conducts market research on Jazz Pharmaceuticals, including monitoring operational risks and issuing price targets.
-
Royal Bank of Canada Mentioned together
RBC provides financial analysis, price targets, and buy ratings for Jazz Pharmaceuticals.
-
Benzinga Mentioned together
Benzinga provides financial news coverage regarding Jazz Pharmaceuticals' earnings.
-
Samsung Wallet Operational
The entities are collaborating to support digital payments convenience.
-
MarketBeat Mentioned together
MarketBeat tracks and reports on company performance data and analyst ratings for Jazz Pharmaceuticals.
-
Norway Shared context
Jazz Pharmaceuticals operates in Norway, evidenced by the regulatory approval of Ziihera.
-
Leerink partners Mentioned together
Leerink partners provided a price target update regarding Jazz Pharmaceuticals.
-
Cannes Shared context
The company's program was held in Cannes and demonstrated measurable healthcare impact.
-
Cramer Mentioned together
Cramer provides investment recommendations regarding Jazz Pharmaceuticals.
-
Eli Lilly and Company Operational
Jazz Pharmaceuticals and Eli Lilly are active competitors within the major pharmaceutical stock market.
-
Jim Cramer Mentioned together
Jim Cramer provided a positive market recommendation for Jazz Pharmaceuticals on Mad Money.
-
Zoetis Operational
Market analysis compares the business strengths and financial performance of Jazz Pharmaceuticals and Zoetis.
-
TD Cowen Mentioned together
TD Cowen tracks Jazz Pharmaceuticals, evidenced by the firm upping its price objective.
-
European Society for Medical Oncology Shared context
Jazz Pharmaceuticals presented clinical trial results at the European Society for Medical Oncology Congress.
-
Liechtenstein Shared context
Jazz Pharmaceuticals operates within the pharmaceutical market context of Liechtenstein.
-
Hoffmann-La Roche Transactional
A drug (Zepzelca) was approved in the market alongside a Roche product (Tecentriq).
-
PharmaMar Transactional
The relationship involved a specific, time-bound partnership where the Phase 3 clinical trial for Jazz's drug was conducted.
-
Deutsche Bank Operational
Jazz Pharmaceuticals engaged with a Deutsche Bank analyst to discuss its development plans.
-
Truist Financial Mentioned together
Truist Financial provided a buy rating and price objective for Jazz Pharmaceuticals.
-
Buy Mentioned together
No evidence was found linking Jazz Pharmaceuticals and Buy.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
4 events- Alan M. Sebulsky was appointed to the Board of Directors of MeiraGTx Holdings PLC, where he has previously served.
- Iambic Therapeutics announced multiple new partnerships, including collaborations with Jazz Pharmaceuticals and AbbVie, and received backing from Qatar Investment Authority and Nvidia.
- The California State Teachers Retirement System has increased its stake in Jazz Pharmaceuticals.
- Jazz Pharmaceuticals and RYTHM are competing in the pharmaceutical market and listed on the Nasdaq stock exchange.
August 2026
7 events- Jazz Pharmaceuticals plans U.S. launch of Ziihera.
- Jazz Pharmaceuticals acquires Actio Biosciences for rare epilepsy portfolio, and the company's investigational drug secures multiple FDA designations.
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.
- Jazz Pharmaceuticals guaranteed notes issued by its subsidiary, Jazz Investments I Limited, on August 26, 2026.
- Vertex Pharmaceuticals and Jazz Pharmaceuticals initiated a collaboration on T-cell engager research programs.
- Analyst coverage and company performance data published regarding Jazz Pharmaceuticals, involving MarketBeat, Royal Bank of Canada, and TD Cowen.
- Dr. Mark D. Smith holds a Clinical Professorship at UC San Francisco, serves on Jazz Pharmaceuticals boards, and was elected to the National Academy of Medicine in 2001.
Show 1 earlier month
June 2026
31 events- Trump-era tariffs are reported to be benefiting certain AI stocks, involving Core & Main.
- Jazz Pharmaceuticals received conditional marketing authorization in Europe and specific product approvals for Ziihera in Norway, Iceland, and Liechtenstein on July 6, 2025.
- Morgan Stanley and Wells Fargo maintained 'Buy' ratings for Jazz Pharmaceuticals, citing benefits from tariffs and onshoring trends for AI stocks.
- Partnership between Jazz Pharmaceuticals, AbCellera, and PharmaMar leverages an antibody discovery engine for a biopharmaceutical based in Ireland.
- Jazz Pharmaceuticals disclosed stock transactions via required filings with the SEC.
- FDA granted approval to Zepzelca in 2025, which was approved in partnership with Roche's Tecentriq.
- A prostate cancer awareness campaign featuring Jazz Pharmaceuticals, George Kittle, and Delanie Walker took place in Cannes.
- Morgan Stanley and Truist Financial have issued rating updates and price targets for Jazz Pharmaceuticals, requiring filings with the SEC.
- Jazz Pharmaceuticals filed required documentation with the SEC regarding market transparency on June 11, 2026.
- Analyst raised price target for Jazz Pharmaceuticals from $281 to $307, driven by product adoption and revenue growth.
- Jazz Pharmaceuticals, headquartered in Dublin, Ireland, participated in the Wells Fargo Healthcare Conference.
- Jazz Pharmaceuticals received conditional marketing approval from the European Commission on July 1, 2025.
- Analyst questions were raised on August 13, 2025, regarding the sustainability of Xywav patient adds for Jazz Pharmaceuticals.
- Microsoft, Elanco, Monster Beverage, and Jazz Pharmaceuticals were cited in thematic investing as examples of diverse winners in the pharmaceuticals segment.
- AbCellera and Jazz Pharmaceuticals are both companies operating within the biomedical industry.
- Jazz Pharmaceuticals announced that Renee Gala was selected as the new CEO of the company on July 10, 2025. Bruce Cozadd previously held the CEO role.
- Jazz Pharmaceuticals sued over LUMRYZ approval, which the FDA granted for narcolepsy treatment, leading to court rulings in the D.C. circuit.
- Jazz Pharmaceuticals and Jeld-Wen faced market challenges and tax inversion merger issues amid an aggressive tariff plan.
- UBS reiterated a Buy rating on Jazz Pharmaceuticals on July 2, 2025.
- Jazz Pharmaceuticals relocated its headquarters to Ireland while an aggressive tariff plan caused markets to tank.
- Jazz Pharmaceuticals is facing inquiries from Bank of America regarding tariff risks and company matters.
- Seamus Mulligan bought shares of Jazz Pharmaceuticals on July 2, 2025.
- Thierry orchestrated the acquisition of Amolyt Pharma by AstraZeneca and the acquisition of his venture Alizé Pharma 2 by Jazz Pharmaceuticals.
- Jazz Pharmaceuticals stock declined 11% on July 8, 2025, while the S&P 500 saw a gain of 5.3%.
- Jazz Pharmaceuticals acquired GW Pharmaceuticals on July 14, 2025, and is now marketing FDA-approved cannabis drugs.
- Benjamin Graham's investment philosophy is noted as guiding stock analysis for Jazz Pharmaceuticals.
- Jazz Pharmaceuticals reported that oncology headwinds offset neuroscience momentum in its portfolio.
- Jazz seeks Priority Review from FDA and announces results from Dublin.
- Jazz Pharmaceuticals acquired Chimerix in April 2025, and the FDA granted accelerated approval to Jazz Pharma's therapy on the same date.
- Jazz Pharmaceuticals has a recently licensed medication called Modeyso, which was licensed as of September 2, 2025.
- Jazz Pharmaceuticals licensed SAN2355 to Saniona for development on August 29, 2025.